B. J. Gertz

2.1k total citations
27 papers, 1.7k citations indexed

About

B. J. Gertz is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Orthopedics and Sports Medicine. According to data from OpenAlex, B. J. Gertz has authored 27 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Oncology and 9 papers in Orthopedics and Sports Medicine. Recurrent topics in B. J. Gertz's work include Bone health and treatments (10 papers), Bone health and osteoporosis research (7 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). B. J. Gertz is often cited by papers focused on Bone health and treatments (10 papers), Bone health and osteoporosis research (7 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). B. J. Gertz collaborates with scholars based in United States, United Kingdom and Belgium. B. J. Gertz's co-authors include Sherry D. Holland, Harry K. Genant, C. H. Chesnut, Steven T. Harris, David Krupa, Arturo G. Porras, Johanna Wittreich, W. F. Kline, B.K. Matuszewski and M. Gail Murphy and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

B. J. Gertz

26 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. J. Gertz United States	21	574	525	373	355	276	27	1.7k
Robert U. Simpson United States	28	165 0.3×	323 0.6×	287 0.8×	640 1.8×	369 1.3×	62	3.0k
Deborah A. Robins United States	17	216 0.4×	191 0.4×	1.8k 4.8×	974 2.7×	629 2.3×	27	2.7k
Alexandra Margeli Greece	26	182 0.3×	163 0.3×	74 0.2×	606 1.7×	196 0.7×	75	2.0k
Chiaki Shigemasa Japan	28	225 0.4×	40 0.1×	622 1.7×	644 1.8×	245 0.9×	138	2.4k
Masayo Yamada Japan	24	138 0.2×	84 0.2×	393 1.1×	296 0.8×	204 0.7×	62	1.4k
M. Martinez-Maldonado United States	20	146 0.3×	46 0.1×	188 0.5×	382 1.1×	190 0.7×	67	1.4k
Lori A. Plum United States	19	142 0.2×	363 0.7×	232 0.6×	373 1.1×	125 0.5×	83	2.2k
Niels Henrik Buus Denmark	24	88 0.2×	99 0.2×	221 0.6×	296 0.8×	468 1.7×	96	2.0k
Oleg Tsuprykov Germany	22	169 0.3×	70 0.1×	403 1.1×	216 0.6×	109 0.4×	33	1.2k
Edward L. Posvar United States	16	414 0.7×	355 0.7×	110 0.3×	547 1.5×	216 0.8×	30	1.7k

Countries citing papers authored by B. J. Gertz

Since Specialization

Citations

This map shows the geographic impact of B. J. Gertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. J. Gertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. J. Gertz more than expected).

Fields of papers citing papers by B. J. Gertz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. J. Gertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. J. Gertz. The network helps show where B. J. Gertz may publish in the future.

Co-authorship network of co-authors of B. J. Gertz

This figure shows the co-authorship network connecting the top 25 collaborators of B. J. Gertz. A scholar is included among the top collaborators of B. J. Gertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. J. Gertz. B. J. Gertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thach, Chau, et al.. (2007). Effects of Etoricoxib and Comparator Nonsteroidal Anti‐Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet. The Journal of Clinical Pharmacology. 47(12). 1521–1531. 16 indexed citations

Schwartz, Jules I., Arturo G. Porras, Peggy H. Wong, et al.. (2002). Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, a potent, highly selective PDE-5 inhibitor for the treatment of erectile dysfunction. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 22(10). 1365–1366.

Cocquyt, V., Simon Van Belle, Robert Reinhardt, et al.. (2001). Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. European Journal of Cancer. 37(7). 835–842. 116 indexed citations

Murphy, M. Gail, Michael R. McClung, Thomas J. Schnitzer, et al.. (2001). Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women¹. The Journal of Clinical Endocrinology & Metabolism. 86(3). 1116–1125. 67 indexed citations

Curtis, Sean, et al.. (2000). Single dose methodology to assess the influence of an α₁‐adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia. British Journal of Clinical Pharmacology. 49(3). 269–273. 4 indexed citations

Depré, Marleen, Elliot Ehrich, Anne Van Hecken, et al.. (2000). Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. European Journal of Clinical Pharmacology. 56(2). 167–174. 78 indexed citations

Murphy, M. Gail, Mark A. Bach, D. Plotkin, et al.. (1999). Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults. Journal of Bone and Mineral Research. 14(7). 1182–1188. 39 indexed citations

Gertz, B. J., John D Clemens, Sherry D. Holland, Wenmin Yuan, & S. L. Greenspan. (1998). Application of a New Serum Assay for Type I Collagen Cross-Linked N-Telopeptides: Assessment of Diurnal Changes in Bone Turnover With and Without Alendronate Treatment. Calcified Tissue International. 63(2). 102–106. 96 indexed citations

Balani, Suresh K., Xin Xu, Vijaya S. Pratha, et al.. (1997). Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.. PubMed. 25(11). 1282–7. 75 indexed citations

10.

Kanis, John А., B. J. Gertz, Frederick R. Singer, & S. Ortolani. (1995). Rationale for the use of alendronate in osteoporosis. Osteoporosis International. 5(1). 1–13. 60 indexed citations

11.

Aloi, Joseph, B. J. Gertz, Mark L. Hartman, et al.. (1994). Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.. The Journal of Clinical Endocrinology & Metabolism. 79(4). 943–949. 58 indexed citations

12.

Gertz, B. J., Ping Shao, Dennis A. Hanson, et al.. (1994). Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. Journal of Bone and Mineral Research. 9(2). 135–142. 172 indexed citations

13.

Gertz, B. J., Sherry D. Holland, W. F. Kline, B.K. Matuszewski, & Arturo G. Porras. (1993). Clinical pharmacology of alendronate sodium. Osteoporosis International. 3(S3). 13–16. 129 indexed citations

14.

Nussbaum, S R, Raymond P. Warrell, Robert K. Rude, et al.. (1993). Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.. Journal of Clinical Oncology. 11(8). 1618–1623. 45 indexed citations

15.

Harris, Steven T., et al.. (1993). The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women.. The Journal of Clinical Endocrinology & Metabolism. 76(6). 1399–1406. 148 indexed citations

16.

Ammann, Patrick, B. J. Gertz, Luc Portmann, et al.. (1992). Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone and Mineral. 18(3). 237–249. 22 indexed citations

17.

O’Doherty, D.P., et al.. (1992). Effects of five daily 1 h infusions of alendronate in paget's disease of bone. Journal of Bone and Mineral Research. 7(1). 81–87. 34 indexed citations

18.

Cantor, P., Ole Olsen, B. J. Gertz, Ida Gjørup, & H. Worning. (1991). Inhibition of Cholecystokinin-Stimulated Pancreaticobiliary Output in Man by the Cholecystokinin Receptor Antagonist MK-329. Scandinavian Journal of Gastroenterology. 26(6). 627–637. 22 indexed citations

19.

Liddle, Rodger A., et al.. (1989). Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.. Journal of Clinical Investigation. 84(4). 1220–1225. 127 indexed citations

20.

Gardner, David G., et al.. (1988). Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro.. Journal of Clinical Investigation. 82(4). 1275–1281. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact